



Personalis, Inc. to Present at ICI-IO Combinations Summit 2019

March 18, 2019

Menlo Park, CA – March 18, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at ICI-IO Combinations Summit 2019 in Boston on Wednesday, March 20, 2019 at 2:30 PM, EDT.

The [presentation](#), entitled “Challenges and Solutions: Enabling multidimensional tumor immunogenomics for advancing biomarker discovery,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunolD NeXT™. In addition to an overview, the presentation will also highlight how this platform can be used to overcome the challenges facing immuno-oncology translational and clinical researchers. By deriving new insights through our industry leading NGS analysis platform, ImmunolD NeXT provides solutions to enable the development of safer, more effective precision oncology therapeutics and combinations.

[ImmunolD NeXT](#) is the first and only platform to provide comprehensive analysis of both a tumor and its microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology; consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Christelle Johnson, PhD, Senior Field Application Scientist, Cancer Genomics & Immuno-Oncology.

About Personalis, Inc.

Personalis, Inc. is a leader in advanced genomics for precision oncology translational research and clinical trials, dedicated to enabling the development of the next generation of oncology therapeutics. The company’s ImmunolD NeXT Platform comprehensively characterizes the tumor and the tumor microenvironment, facilitating the analysis of key predictive and investigational oncology biomarkers from a single sample. The Personalis [Clinical Laboratory](#) is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ([@PersonalisInc](#)).

Media Contact for Personalis:

Jennifer Havlek

pr@personalis.com

www.personalis.com

650-752-1300